Use our Cohort Matrix to quickly scan and compare what types of data are available from our cohorts. For more detailed information about our cohorts, please visit the Cohort Directory.

info_outline

Explore by:

  • Viewing cohort overviews and categories
  • Click cohort names to view them in more detail
  • Click available cohort categories to go directly to their summary

Showing 41 cohorts


Airwave 53,280 2004 17+ MF Direct access via Portal - collaboration dicsussion with Airwave facilitated Baseline screening, survey, cognitive, and food diary data
AMPLE 80 2013 60+ MF Direct access via Portal Please enquire
BDR 2,963 2009 65+ MF Direct access via Portal and external data upload facilitated Clinical assessment, exome sequencing and Neurochip data, further data available on request from UKBBN and EGA
Cam-CAN 2,683 2010 18-87 MF Direct application to cohort needed after DPUK application submitted Home interview and imaging data
CamPaIGN 142 2000 30+ MF Direct access via Portal Full cohort data
CaPS 2,512 1979 45-59 M Direct access via Portal Phases 1-5 data
MRC CFAS 18,005 1989 65+ MF Direct access via Portal Full cohort data
CFAS II 7,524 2008 65+ MF Direct access via Portal Full cohort data
CHARIOT 24,509 2011 60-85 MF Please enquire Please enquire
CHARIOT: PRO Main Study 712 2013 60-85 MF Please enquire Please enquire
CHARIOT: PRO Sub Study 225 2015 60-85 MF Please enquire Please enquire
Cygnus 500 2016 18+ MF Direct access via Portal Please enquire
DIAN 437 2008 18+ MF Direct access via Portal Study-specific subset on request
EHAS Ongoing Recruitment 2016 18+ MF Please enquire Please enquire
EHBS Ongoing Recruitment 2016 45-75 MF Please enquire Please enquire
ELSA 11,391 2002-2003 50-100 MF Direct access via Portal Full cohort data, waves 0-8
EPIC Norfolk 25,639 1993-1997 40-79 MF Direct access via Portal alongside cohort variable selection Study-specific subset on request
EPINEF 2,008 2014 60+ MF Direct access via Portal Baseline cohort data
Generation Scotland 23,960 2006 18-100 MF Direct access via Portal Baseline cohort data
GENFI 515 2015 18 + MF Please enquire Please enquire
GERAD 14,851 2011 MF Direct access via Portal GWAS and summary statistics
HWW 29,495 2015 16+ MF Access via HWW UKSeRP Please enquire
ICICLE-PD 318 2009 18+ MF Direct access via Portal Baseline cohort data
Lewy Pro 100 2013 60+ MF Direct access via Portal Please enquire
Lothian Birth Cohort 1936 1,091 1947 (2004) 11 (70-72) MF Direct access via Portal Study-specific subset on request
Memento 2,323 2011 18+ MF Direct access via Portal Baseline to 24 month follow-up
Million Women 1,319,475 1996-2001 50-64 F Direct access via Portal Study-specific subset on request
MRC NSHD (1946 Birth Cohort) 5,362 1946 Birth MF Direct access via Portal Study-specific subset on request
NICOLA 8,504 2014 50+ MF Direct access via Portal Please enquire
NIMROD 276 2013 50+ MF Direct access via Portal Please enquire
OPDC Discovery 1,589 2009 18 + MF Direct access via Portal Baseline cohort data
PaMIR 400 2013 18+ MF Please enquire Please enquire
PICNICS 282 2008 18+ MF Direct access via Portal Cohort data from baseline to 54 month follow-up
PREVENT 230 2014 40-59 MF Please enquire Please enquire
PRIME 2,745 1991 50-60 M Direct access via Portal Please enquire
PROTECT 14,000 2015 50+ MF Direct application to cohort needed after DPUK application submitted Study-specific subset on request
SABRE 4,858 1988 40-69 MF Direct access via Portal Study-specific subset on request
SMC Amyloid PET 120 2016 50+ MF Direct access via Portal Baseline cohort data
TRACK HD 366 2008 18-65 MF Direct access via Portal Baseline cohort data
UK Biobank 502,655 2006-2010 40-69 MF Direct application to cohort needed after DPUK application submitted Study-specific subset on request
Whitehall II 10,308 1985 35-55 MF Direct access via Portal alongside cohort variable selection Study-specific subset on request, from DPUK-specific version of waves 1-12



Showing 41 cohorts


Airwave x x x x x x . . x x x x x . x . x x . x x .
AMPLE x x . . x . x x x x x x x . x . x x x x x .
BDR x x . . x . x x x x x x x . x . x x x x . .
Cam-CAN x x . . x . x x x x x x x x x . x x x . . .
CamPaIGN x x . . x . x x . x x x x . x . x x . x . .
CaPS x x . . x . x . x x x x x . x . x x . . x .
MRC CFAS x x . . x . x x x x x x x . x . x x . x . .
CFAS II x x . . x . x . x x x x x . x . x x . x . .
CHARIOT x x . . . . . . . . . . . . . . . . . . . .
CHARIOT: PRO Main Study x x . . x . x x x x x x x . x . x x . x . .
CHARIOT: PRO Sub Study x x . . x . x x x x x x x . x . x x x x x .
Cygnus x x . . x . x . x . x x x . x . . x . . . .
DIAN x x . . x . x x . x x . . . x . x x x x . .
EHAS x x . . x . x . x . x x . . x . . . . . . .
EHBS x x . . x . x . x . x x x . x . x x . x . .
ELSA x x x x x x x x x x . x x x x x x x . x . .
EPIC Norfolk x x . . x . x . x x x x x . x . x x x x x x
EPINEF x x . . x . x x x x x x . . x . x x x x x .
Generation Scotland x x . . x . x . x x x x x . x . x x x x x .
GENFI x x x x x x . . x x x x . . x . x x x x . .
GERAD x x . . x . x x . x x x x . x . x x . x x .
HWW x x . . . . . . x . . x . . x . . . . . . .
ICICLE-PD x x . . x . x x x x x x x . x . x x x x x .
Lewy Pro x x . . x . x x x x x x x . x . x x x x x .
Lothian Birth Cohort 1936 x x . . x . x x x x x x x . x . x x x x x .
Memento x x x . x x x x . x x x . x x . x x x x . .
Million Women x x . . x . x . x x x x x . x . x x . . x .
MRC NSHD (1946 Birth Cohort) x x . . x . x x x x x x x x x . x x x x x .
NICOLA x x . . x . x x x x . x x . x . x x x x x .
NIMROD x x . . x . x x x x x x x . x . x x x . . .
OPDC Discovery x x . . x . x x x x x x x . x . x x x x x x
PaMIR x x . . . . . . . . x . . . x . . x x . . .
PICNICS x x . . x . x x . x x x x . x x x x . x . .
PREVENT x x . . x . x x x x x x x . x . x x x x x .
PRIME x x . . x . x . . . . x x . x . x x . . x .
PROTECT x x . . x . . x . x . x x . x . x x . x . .
SABRE x x . . x . x . x x . x x . x . x x x x x .
SMC Amyloid PET x x . . x . . . . . x x . . x . x x . x x .
TRACK HD x x . . x . x . x x x x x . x . x x x x . .
UK Biobank x x . . x . x . x x x x x x x . x x x x x x
Whitehall II x x x . x . x x x x x x x . x . x x x x x .